CLAIMS

1. A method of treating female sexual dysfunction induced by one or more antidepressants, previously administered to a female subject, the method comprising applying topically a composition comprising CBD ("CBD-containing composition"), said composition being applied to the mucosal surface of female subject's genital (arousal) area(s), wherein the composition is applied in the amount and for a period of time prior to a sexual activity such that sexual dysfunction of the subject is ameliorated during the sexual activity.

2. The method of claim 1, wherein said topical composition is formulated as a lotion, an ointment, a cream, a suspension, a paste, a gel, a balm, a tincture, an emulsion, a serum, any one of which is applied to the female genitalia.

3. The method of claim 1, wherein the genital area includes genitalia with absorptive mucosa, comprising one or more of: the introitus, the vulva, the labia minora, the clitoris and the vaginal vault.

4. The method of claim 1, wherein the antidepressant causing sexual dysfunction is selected from an SSRI, an SNRI, a tricyclic antidepressant, and a tetracyclic depressant.

5. The method of claims 4, wherein a) the SSRI is selected from sertraline, citalopram, fluoxetine, escitalopram, paroxetine, fluvoxamine, duloxetine, venlafaxine, and desvenlafaxine;
b). the SNRI is selected from duloxetine, venlafaxine, desvenlafaxine, milnacipran, and levomilnacipran;
c) the tricyclic antidepressant is selected from clomipramine, trimipramine, amitriptyline, desipramine, imipramine, lofepramine, doxepin, nortriptyline, amoxapine, and protriptyline; and/or the tetracyclic antidepressant is selected from maprotiline and mirtazapine.

6. The method as in claim 1, wherein the female subject is human and has been diagnosed with one or more disorders or conditions selected from the group consisting of major depressive disorder (MDD), persistent depressive disorder or dysthymia, melancholic depression, anxiety disorder (e.g., generalized anxiety disorder (GAD) and social anxiety disorder (SAD)), attention-deficit hyperactivity disorder (ADHD), obsessive–compulsive disorder (OCD), bulimia nervosa (bulimia), panic disorder, premenstrual dysphoric disorder, menopause-associated vasomotor symptoms, fibromyalgia, neuropathic pain, post-traumatic stress disorder (PTSD), diabetic peripheral neuropathy (DPN), and chemotherapy-induced neuropathy.

7. The method of claim 1, wherein the female sexual dysfunction is characterized by one or more of the following characteristics: difficulty achieving arousal and/or insufficient lubrication, difficulty in achieving and maintaining engorgement, and difficulty in achieving and maintaining lubrication.

8. The method of claim 1, wherein the female sexual dysfunction is characterized by one or more of the following characteristics: difficulty achieving orgasm, low orgasm intensity, or anorgasmia.

9. The method of claim 1, wherein the female sexual dysfunction is characterized to lack of sexual desire or interest.

10. The method of claim 1, wherein the female subject is premenopausal.

11. The method of claim 1, wherein the female subject is post-menopausal.

12. The method as in claim 1, wherein the subject has been previously treated with, but did not satisfactorily respond to, one or more of the following treatments: (1) change of the time the antidepressant medication is taken, (2) drug holidays, (3) decrease the dose of the medication, (4) switching to or addition of mirtazapine, (5) switching to or addition of bupropion, (6) addition of phosphodiesterase inhibitors (e.g., vardenafil, avanafil, and udenafil),
(9) topical testosterone, (7) amantadine, (8) yohimbine, (9) switching to or addition of trazodone, (10) stimulants such as methylphenidate, (11) behavioral therapy, (12) dietary supplements, e.g., saffron, and (13) acupuncture.

13. The method as in claim 1, wherein the female subject is further treated with one or more of the following treatments: (1) change of the time the antidepressant medication is taken, (2) drug holidays, (3) decrease the dose of the medication, (4) switching to or addition of mirtazapine, (5) switching to or addition of bupropion, (6) addition of phosphodiesterase inhibitors (e.g., vardenafil, avanafil, and udenafil), (9) topical testosterone, (7) amantadine, (8) yohimbine, (9) switching to or addition of trazodone, (10) stimulants such as methylphenidate, (11) behavioral therapy, (12) dietary supplements, e.g., saffron, and (13) acupuncture.

14. The method of claim 1, wherein the amelioration of the sexual dysfunction is exhibited by one or both of the following parameters:

i. vaginal and clitoral smooth muscle relaxation; and

ii. increased vaginal and clitoral blood flow.

15. The method of claim 1, wherein the amelioration of the sexual dysfunction is exhibited by one or more of the following subjectively self-reported outcomes including:

iii. "increased lubrication/wetness during sexual activity";

iv. "reaching orgasm more often";

v. "greater ease or achieving orgasm";

vi. "being more satisfied";

vii. "higher level of sexual desire"; and

viii. "reduction in pain during sexual activity".

16. The method of claim 1, wherein the total amount of CBD applied is from 5 mg to 1,000 mg of CBD, preferably 10-100 mg of CBD, more preferably, 20-40 mg of CBD.

17. The method of claim 1, wherein the composition is applied 1-60 min prior to sexual activity, preferably, 5-40 min, more preferably 15-20 min.

18. The method of claim 1, wherein the CBD-containing composition is applied at 5-30 mins prior to the sexual activity.

19. The method of claim 1, where is CBD is hemp-derived and/or contain less 0.3% THC by weight.

20. The method of claim 1, wherein the CBD-containing composition is provided in a single-use container.

21. The method of claim 1, wherein the CBD-containing composition further comprises preservative(s) and is provided in a multi-use container.

22. The method of claim 1, wherein the concentration of CBD in the composition is from 1 mg/mL to 40 mg/mL, preferably, 5 mg/mL to 20 mg/mL, more preferably, 10 mg/mL.

23. The method of claim 1, wherein the subject is afflicted with a disorder selected from (1) Sexual Interest/Arousal Disorder (SIAD) and (2) Female Orgasmic Disorder.

24. The method of claim 23, wherein the subject, upon having been treated with the CBD-containing composition for 3-6 months, reports arousal and or orgasmic improvements as measured by FSFI, wherein the improvement in sexual interest/arousal domain is by 1-2 points, and by 1-2 points in the orgasm domain of the FSFI.

25. The method of claim 1, wherein the off-set time following the application of the CBD-containing composition is 0.5-5 hrs, preferably, 1-3 hrs, more preferably 1-2 hrs.

26. The method of claim 1, wherein a phosphodiesterase type 5 (PDE-5) inhibitor (e.g., sildenafil, tadalafil, vardenafil, avanafil, udenafil) is added to the CBD-containing composition.

27. The method of claim 1, wherein another direct smooth muscle relaxant (prostaglandin E1, papaverine, minoxidil) is added to the CBD-containing composition.

28. The method of claim 1, wherein: a) an alpha-blocker (e.g., phentolamine); b) flibanserin and/or c) bremelanotide is/are added to the CBD-containing composition.to augment sexual desire.

29. The method as in claim 1, wherein the subject is additionally treated with a PDE-5 inhibitor which is administrated orally, or topically similarly to CBD- containing composition, before, concurrently, or after the application of the CBD-containing composition.

30. The method as in claim 1, wherein the subject was previously treated with an anti-depressant that induced sexual dysfunction and has persistent sexual dysfunction despite discontinuation of the anti-depressant therapy.